Pirin Inhibits FAS‐Mediated Apoptosis to Support Colorectal Cancer Survival
Source abstract
Abstract
Abstract Resistance to immunotherapy in colorectal cancer (CRC) is associated with obstruction of FAS (Apo‐1 or CD95)‐dependent apoptosis, a hallmark of cancer. Here it is demonstrated that the upregulation of pirin (PIR) protein in colon cancers promotes tumorigenesis. Knockout or inhibition of PIR dramatically increases FAS expression, FAS‐dependent apoptosis and attenuates colorectal tumor formation in mice. Specifically, NFκB2 is a direct transcriptional activator of FAS and robustly suppressed by PIR in dual mechanisms. One is the disruption of NFκB2 complex (p52‐RELB) association with FAS promoter, the other is the inhibition of NIK‐mediated NFκB2 activation and nuclear translocation, leading to the inability of active NFκB2 complex toward the transcription of FAS. Furthermore, PIR interacts with FAS and recruits it in cytosol, preventing its membrane translocation and assembling. Importantly, knockdown or knockout of PIR dramatically sensitizes cells to FAS mAb‐ or active CD8+ T cells‐triggered cell death. Taken together, a PIR‐NIK‐NFκB2‐FAS survival pathway is established, which plays a key role in supporting CRC survival.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Research and Treatments · Glycosylation and Glycoproteins Research · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences Xiamen University Xiamen 361102 China
Funding
National Natural Science Foundation of China · China Postdoctoral Science Foundation · Xiamen Municipal Bureau of Science and Technology
References (58)
Show source-provided references
1. 10.1074/jbc.272.13.848210.1074/jbc.272.13.8482 ↗
2. 10.3390/antiox1102026210.3390/antiox11020262 ↗
3. 10.1038/sj.onc.120642810.1038/sj.onc.1206428 ↗
4. 10.1186/1471-2121-11-510.1186/1471-2121-11-5 ↗
5. 10.1016/j.ajpath.2011.01.01910.1016/j.ajpath.2011.01.019 ↗
6. 10.1021/acs.biochem.7b0052810.1021/acs.biochem.7b00528 ↗
7. 10.1038/leu.2009.24710.1038/leu.2009.247 ↗
8. 10.1038/sj.onc.120271710.1038/sj.onc.1202717 ↗
9. 10.1073/pnas.122174311010.1073/pnas.1221743110 ↗
10. 10.1007/s11010-013-1931-010.1007/s11010-013-1931-0 ↗
11. 10.1089/ars.2017.717610.1089/ars.2017.7176 ↗
12. 10.1378/chest.125.6.223810.1378/chest.125.6.2238 ↗
13. 10.1074/jbc.M40325820010.1074/jbc.M403258200 ↗
14. 10.1038/sj.cdd.440091410.1038/sj.cdd.4400914 ↗
15. 10.1016/j.molcel.2016.01.00910.1016/j.molcel.2016.01.009 ↗
16. 10.1126/science.288.5475.232810.1126/science.288.5475.2328 ↗
17. 10.1038/cdd.2011.12110.1038/cdd.2011.121 ↗
18. 10.1016/j.bcp.2019.01.01510.1016/j.bcp.2019.01.015 ↗
19. 10.1038/nrc77610.1038/nrc776 ↗
20. 10.1038/nm1296-136110.1038/nm1296-1361 ↗
21. 10.1093/emboj/18.7.182410.1093/emboj/18.7.1824 ↗
22. 10.1128/MCB.23.10.3623-3635.200310.1128/MCB.23.10.3623-3635.2003 ↗
23. 10.1074/jbc.M50986620010.1074/jbc.M509866200 ↗
24. 10.1007/s00428-005-1264-910.1007/s00428-005-1264-9 ↗
25. 10.3109/1071576920907951510.3109/10715769209079515 ↗
26. 10.1038/sj.onc.120995410.1038/sj.onc.1209954 ↗
27. 10.1038/cr.2010.17710.1038/cr.2010.177 ↗
28. 10.1038/nri.2017.5210.1038/nri.2017.52 ↗
29. 10.1007/s00125-015-3817-z10.1007/s00125-015-3817-z ↗
30. 10.1038/ncb87210.1038/ncb872 ↗
31. 10.1038/nchembio.42310.1038/nchembio.423 ↗
32. 10.1016/j.cels.2015.12.00410.1016/j.cels.2015.12.004 ↗
33. 10.1073/pnas.050658010210.1073/pnas.0506580102 ↗
34. 10.1074/jbc.M115.64533310.1074/jbc.M115.645333 ↗
35. 10.1080/19396368.2017.142204610.1080/19396368.2017.1422046 ↗
36. 10.1186/1755-8794-4-910.1186/1755-8794-4-9 ↗
37. Guo C. L. · Zhonghua Gan. Zang Bing Za Zhi · 2018 · 26 · 125
38. 10.1084/jem.183.3.107110.1084/jem.183.3.1071 ↗
39. 10.1126/science.270.5239.118910.1126/science.270.5239.1189 ↗
40. Kitamura T. · J. Vis. Exp. · 2019 · 143 · 1
41. 10.1586/14737140.8.4.56110.1586/14737140.8.4.561 ↗
42. 10.1016/j.immuni.2013.10.00310.1016/j.immuni.2013.10.003 ↗
43. 10.1016/j.immuni.2009.01.00110.1016/j.immuni.2009.01.001 ↗
44. 10.1084/jem.187.1.12310.1084/jem.187.1.123 ↗
45. 10.1038/s41467-017-00784-110.1038/s41467-017-00784-1 ↗
46. 10.1038/s41392-020-0205-z10.1038/s41392-020-0205-z ↗
47. 10.1074/jbc.M112.35627910.1074/jbc.M112.356279 ↗
48. 10.1038/s41590-020-00829-610.1038/s41590-020-00829-6 ↗
49. 10.1038/s12276-018-0191-110.1038/s12276-018-0191-1 ↗
50. 10.1097/PPO.000000000000030310.1097/PPO.0000000000000303 ↗
51. 10.1158/1541-7786.MCR-18-045510.1158/1541-7786.MCR-18-0455 ↗
52. 10.1038/s41419-020-03232-z10.1038/s41419-020-03232-z ↗
53. 10.1038/nm.396710.1038/nm.3967 ↗
54. Alessandro B. · Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives · 2018 · 4 · 55
55. Jozefczuk J. · J. Vis. Exp. · 2012 · 64 · 1
56. 10.1053/j.gastro.2018.11.03610.1053/j.gastro.2018.11.036 ↗
57. 10.1016/j.celrep.2020.03.00510.1016/j.celrep.2020.03.005 ↗
58. Taylor J. D. · Methods Mol. Biol. · 1994 · 30 · 263